Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated (PRLD) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PRLD · as of Sep 30, 2025
Ownership Breakdown
46
Institutional Holders
▼ 4 vs Q2
$39.11M
Total Inst. Value
▲ $17.12M vs Q2
78.50M
Shares Outstanding
freeFloat 58.65%
27.16M
13F Shares Held
▼ 26,105 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PRLD largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC pharmaceutical preparations | 10.91M | 14.36% | 14.36% | $15.71B | Nov 14, 2025 | — held |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 10.12M | 13.32% | 13.32% | $14.58B | Nov 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 1.15M | 1.51% | 1.51% | $1.65B | Nov 14, 2025 | ▲ 898.6K |
VANGUARD GROUP INC pharmaceutical preparations | 992.9K | 1.31% | 1.31% | $1.43B | Nov 7, 2025 | ▲ 60.3K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 876.3K | 1.15% | 1.15% | $1.26B | Nov 14, 2025 | ▼ 51.3K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 544.0K | 71.58% | 71.58% | $783.36M | Nov 13, 2025 | ▼ 37.8K |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 540.6K | 71.13% | 71.13% | $777.00M | Nov 13, 2025 | — held |
MORGAN STANLEY pharmaceutical preparations | 284.2K | 37.40% | 37.40% | $409.25M | May 27, 2026 | ▼ 179 |
BLACKROCK, INC. pharmaceutical preparations | 265.0K | 34.87% | 34.87% | $381.56M | Nov 12, 2025 | ▼ 167.6K |
TWO SIGMA ADVISERS, LP pharmaceutical preparations | 222.7K | 29.30% | 29.30% | $320.69M | Nov 14, 2025 | ▼ 2.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
8
Increased
+995.9K shares4
New Positions
first time holders23
Decreased
−608.6K shares4
Sold Out
fully exitedNet shares change (top 50)
+387.3K
+995.9K / −608.6K
Net new holders
-15
4 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PRLD insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
1
Sell transactions
7.00
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Morris Charles Q Chief Medical Officer | May 1, 2026 | Award | 450,000 | $4.70 | $2.12M | 450.0K | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Apr 27, 2026 | J-Other | 1,407,000 | $0.00 | $140.7 | 6.48M | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Apr 27, 2026 | J-Other | 1,407,000 | $0.00 | $140.7 | 1.41M | Form 4 ↗ |
Bonita David P
| Apr 21, 2026 | Purchase | 1,689,189 | $4.44 | $7.50M | 11.81M | Form 4 ↗ |
Bonita David P
| Apr 21, 2026 | Purchase | 1,126,126 | $4.44 | $5.00M | 1.13M | Form 4 ↗ |
ORBIMED ADVISORS LLC
| Apr 21, 2026 | Purchase | 1,689,189 | $4.44 | $7.50M | 11.81M | Form 4 ↗ |
ORBIMED ADVISORS LLC
| Apr 21, 2026 | Purchase | 1,126,126 | $4.44 | $5.00M | 1.13M | Form 4 ↗ |
BAKER BROS. ADVISORS LP
| Apr 21, 2026 | Purchase | 2,137,651 | $0.00 | $213.765 | 20.11M | Form 4 ↗ |
BAKER BROS. ADVISORS LP
| Apr 21, 2026 | Purchase | 114,601 | $0.00 | $11.46 | 1.68M | Form 4 ↗ |
Combs Andrew Chief Chemistry Officer | Feb 4, 2026 | Award | 230,000 | $2.30 | $529.0K | 230.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Prelude Therapeutics Incorporated (PRLD) is primarily owned by institutional investors, who hold approximately 34.6% of total shares outstanding. Company insiders own approximately 41.35%, while retail and public investors account for the remaining 24.05%.
The largest institutional shareholder of Prelude Therapeutics Incorporated is ORBIMED ADVISORS LLC, holding approximately 10.91 million shares — equal to 14.36% of outstanding shares — as of September 30, 2025.
A total of 46 institutional investors currently hold PRLD stock, with a combined institutional value of approximately $39,111,967 as of the most recent 13F filing period.
Frequently asked questions
PRLD ownershipPrelude Therapeutics Incorporated (PRLD) is primarily owned by institutional investors, who hold approximately 34.6% of shares. The largest shareholder is ORBIMED ADVISORS LLC with a 14.36% stake. Company insiders hold 41.35%. Data sourced from SEC Form 13F as of September 30, 2025.